AZD-3759

CAS No. 1626387-80-1

AZD-3759 ( AZD-3759 )

Catalog No. M12405 CAS No. 1626387-80-1

A potent, oral active, BBB-penetrating EGFR inhibitor (IC50=7.2 nM, L858R pEGFR).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 35 In Stock
25MG 56 In Stock
50MG 80 In Stock
100MG 125 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    AZD-3759
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent, oral active, BBB-penetrating EGFR inhibitor (IC50=7.2 nM, L858R pEGFR).
  • Description
    A potent, oral active, BBB-penetrating EGFR inhibitor (IC50=7.2 nM, L858R pEGFR); fully penetrate the blood-brain barrier (BBB), with equal free concentrations in the blood, cerebrospinal fluid, and brain tissue; causes tumor regression in subcutaneous xenograft, leptomeningeal metastasis (LM), and brain metastasis (BM) lung cancer models and prevents the development of BM in nude mice.Lung Cancer Phase 1 Clinical
  • Synonyms
    AZD-3759
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR(exon19Del);EGFR(L858R);EGFR(WT)
  • Research Area
    Cancer
  • Indication
    Lung Cancer

Chemical Information

  • CAS Number
    1626387-80-1
  • Formula Weight
    459.90
  • Molecular Formula
    C22H23ClFN5O3
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    O=C(N1[C@H](C)CN(C)CC1)OC2=CC3=C(NC4=CC=CC(Cl)=C4F)N=CN=C3C=C2OC
  • Chemical Name
    1-Piperazinecarboxylic acid, 2,4-dimethyl-, 4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl ester, (2R)-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Zeng Q, et al. J Med Chem. 2015 Oct 22;58(20):8200-15.
2. Yang Z, et al. Sci Transl Med. 2016 Dec 7;8(368):368ra172.
3. Tan CS, et al. Lung Cancer. 2016 Mar;93:59-68.
molnova catalog
related products
  • Poziotinib hydrochlo...

    Poziotinib hydrochloride irreversibly inhibits EGFR (HER1 or ErbB1), including EGFR mutants, HER2, and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors.?It is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor with potential antineoplastic activity.?

  • Cetuximab (anti-EGFR...

    Cetuximab (anti-EGFR) is an inhibitor of epidermal growth factor receptor (EGFR).

  • Nimotuzumab

    Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).